Business
Sareum to Present at the ICCS 2017
Sareum to Present at the ICCS 2017.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 3717I Sareum Holdings PLC 19 June 2017 \n\n\n\n\n\n(AIM: SAR)\n\n\n \n\n\n\n\n \nSareum Holdings PLC\n(\"Sareum\" or the \"Company\")\nSareum to Present at the International Cancer Cluster Showcase 2017\nDr Tim Mitchell, CEO of Sareum Holdings plc (AIM:SAR), the specialist cancer drug discovery and development business, will deliver a presentation at the 6th annual International Cancer Cluster Showcase, being held today at the San Diego Convention Center. \nDr Mitchell will be showcasing Sareum and its cancer research pipeline as one of three companies from the UK \"Golden Triangle\" biotechnology cluster. \nCompanies from nine North American and European innovation hubs are scheduled to present at the event, which is organised as a satellite to the BIO International Convention, the world's largest gathering for the global biotech industry. Over 200 representatives from the international oncology community are expected to participate in this focused network meeting.\nhttp://www.internationalcancercluster.org/\nDr Tim Mitchell, CEO of Sareum, commented: \"We are delighted that Sareum has been selected to represent British cancer research at this prestigious event.\"\nFor further information, please contact: \n\n\n\n\nSareum Holdings plc\n\n\n \n\n\n\n\nTim Mitchell\n\n\n01223 497 700\n\n\n\n\nWH Ireland Limited (Nominated Adviser and Co-Broker)\n\n\n\n\nChris Fielding / James Sinclair-Ford\n\n\n020 7220 1666\n\n\n\n\nHybridan LLP (Co-Broker)\n\n\n \n\n\n\n\nClaire Noyce\n\n\n020 3764 2341\n\n\n\n\nThe Communications Portfolio (Sareum Media enquiries)\n\n\n \n\n\n\n\nAriane Comstive\[email protected] \n\n\n07785 922 354\n\n\n\n\nNotes for editors: \nSareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease, and licensing them to pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.\nSareum operates an outsourced research model, working with international collaborators and a world-wide network of research providers. Its most advanced programme (Chk1) commenced clinical trials in May 2016 and was licensed to NASDAQ-listed Sierra Oncology in September 2016.\nSKIL® (Sareum Kinase Inhibitor Library) is Sareum's drug discovery ...